Revolution Medicines Inc at Cowen Healthcare Conference (Virtual) Transcript
Welcome back to the Cowen Health Care Conference. Next session here, we're very glad to have with us Mark Goldsmith, the CEO of Revolution Medicines. We're going to do some Q&A in a minute. But we'll start off with Mark [giving you] a couple minute overview, a status update of the company, and then we'll dive into specific questions. I think he's also going to share a couple of slides as he does that. So with no further ado, Mark, the floor is yours.
Thanks very much, Marc. We really appreciate the chance to talk with you today. I just thought I'd start by reminding everybody that targeted therapies are still needed for very common, serious and genetically defined RAS-addicted cancers. And this slide attempts to convey the segmentation of those RAS-addicted cancers, representing in total roughly 230,000 new cancer cases in the U.S. alone each year. And with this segmentation, it's evident how genetic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |